Biosimilar Market to Hit $178 Billion in 2024
May 17, 2021
In 2006, the European Medicines Agency approved its first biosimilar. Omnitrope was developed in cases of growth hormone deficiency. Now, 15 years later, the biosimilar market continues to grow and is expected to hit a staggering $178 billion in three years.
“The first biosimilar to receive marketing authorization by the European Commission occurred 15 years ago for Sandoz’s Omnitrope for the treatment of growth disturbance in children and adults. The biosimilar market has grown immensely since then and is estimated to reach $178 billion in 2024.” Read more here.
(Source: Xcenda, 5/13/21)